AR066783A1 - Proceso para proporcionar un relajante muscular estable a la temperatura a base del componente neurotoxico de toxina botulinica - Google Patents

Proceso para proporcionar un relajante muscular estable a la temperatura a base del componente neurotoxico de toxina botulinica

Info

Publication number
AR066783A1
AR066783A1 ARP080102287A ARP080102287A AR066783A1 AR 066783 A1 AR066783 A1 AR 066783A1 AR P080102287 A ARP080102287 A AR P080102287A AR P080102287 A ARP080102287 A AR P080102287A AR 066783 A1 AR066783 A1 AR 066783A1
Authority
AR
Argentina
Prior art keywords
stable
muscle relaxant
providing
neurotoxic component
temperature based
Prior art date
Application number
ARP080102287A
Other languages
English (en)
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07010912A external-priority patent/EP1997509A1/en
Priority claimed from EP07020025A external-priority patent/EP2048156A1/en
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of AR066783A1 publication Critical patent/AR066783A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38Albumins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893Botulinum neurotoxin (3.4.24.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invencion proporciona un proceso para proporcionar un relajante muscular, a temperaturas por encima de 6°C, con preferencia por encima de 25°C, donde dicho relajante muscular es una solucion reconstituida que comprende el componente neurotoxico de toxina botulínica libre de proteínas formadoras de complejos, el cual exhibe por lo menos una de las siguientes características, con más preferencia todas las características de la a) a la d): a) Es estable a temperaturas de almacenamiento por encima de 20°C, b) Es estable en presencia de conservantes y/o analgésicos, c) Es resistente contra ciclos de ôcongelacion y descongelacionö, d) Es estable si se almacena en envases de diferentes materiales.
ARP080102287A 2007-06-01 2008-05-30 Proceso para proporcionar un relajante muscular estable a la temperatura a base del componente neurotoxico de toxina botulinica AR066783A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US93262407P 2007-06-01 2007-06-01
EP07010912A EP1997509A1 (en) 2007-06-01 2007-06-01 Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin
US99885807P 2007-10-12 2007-10-12
EP07020025A EP2048156A1 (en) 2007-10-12 2007-10-12 Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin

Publications (1)

Publication Number Publication Date
AR066783A1 true AR066783A1 (es) 2009-09-09

Family

ID=40074591

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP080102286A AR066782A1 (es) 2007-06-01 2008-05-30 Proceso para proporcionar un relajante muscular estable a la temperatura a base del componente neurotoxico de la oxina botulinica en forma solida
ARP080102287A AR066783A1 (es) 2007-06-01 2008-05-30 Proceso para proporcionar un relajante muscular estable a la temperatura a base del componente neurotoxico de toxina botulinica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP080102286A AR066782A1 (es) 2007-06-01 2008-05-30 Proceso para proporcionar un relajante muscular estable a la temperatura a base del componente neurotoxico de la oxina botulinica en forma solida

Country Status (15)

Country Link
US (2) US20090010965A1 (es)
EP (2) EP2164861A1 (es)
JP (2) JP2010529000A (es)
KR (2) KR20100020972A (es)
CN (2) CN101720331A (es)
AR (2) AR066782A1 (es)
AU (2) AU2008256419A1 (es)
BR (2) BRPI0812245A2 (es)
CA (2) CA2686637A1 (es)
IL (2) IL202129A0 (es)
MX (2) MX2009012990A (es)
RU (1) RU2009149604A (es)
TW (2) TW200914039A (es)
WO (2) WO2008145359A1 (es)
ZA (2) ZA200907875B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
AR061669A1 (es) 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
RU2011125775A (ru) 2008-12-31 2013-02-10 Реванс Терапьютикс, Инк. Составы на основе ботулотоксина для инъекции
US20100184685A1 (en) * 2009-01-19 2010-07-22 Zavala Jr Gerardo Systems and methods for treating post- operative, acute, and chronic pain using an intra-muscular catheter administrated combination of a local anesthetic and a neurotoxin protein
CA2751311C (en) * 2009-02-19 2019-08-06 Merz Pharma Gmbh & Co. Kgaa Means and methods for manufacturing highly pure neurotoxin
EP2248518B1 (en) * 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
CA2757637C (en) * 2009-04-27 2017-10-24 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the amount of neurotoxin polypeptide and of its catalytic and proteolytic activities
JP6043627B2 (ja) 2009-06-25 2016-12-14 ルバンス セラピュティックス インク.Revance Therapeutics,Inc. アルブミン非含有ボツリヌス毒素製剤
HUE041599T2 (hu) * 2009-10-21 2019-05-28 Revance Therapeutics Inc Eljárások és rendszerek nem-komplexált botulinum neurotoxin tisztítására
EP3241547B1 (en) * 2011-03-31 2020-05-20 Medy-Tox Inc. Lyophilized preparation of botulinum toxin
KR101135486B1 (ko) * 2011-05-25 2012-04-13 함종욱 보툴리눔 에이형 독소의 액상제품
KR101357999B1 (ko) * 2012-03-20 2014-02-03 함종욱 보툴리눔 에이형 독소의 액상제품
CN107106780B (zh) * 2014-12-23 2020-10-16 莫茨制药有限及两合公司 肉毒杆菌毒素预填充式容器
JP6813492B2 (ja) * 2015-02-03 2021-01-13 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン ボツリヌス毒素充填済み容器
EP3070539A1 (fr) * 2015-03-17 2016-09-21 Omega SA Montre-bracelet comprenant un cadran muni d'index lumineux
WO2018038301A1 (en) * 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
MX2020014330A (es) 2018-12-26 2021-03-09 Caregen Co Ltd Composicion para relajacion muscular.
WO2020138674A1 (ko) 2018-12-26 2020-07-02 (주)케어젠 근육 이완용 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
AU2003231878A1 (en) * 2002-05-31 2003-12-19 Solux Corporation Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
EP1786459B1 (en) * 2004-07-26 2014-02-12 Merz Pharma GmbH & Co. KGaA Therapeutic composition whit a botulinum neurotoxin
DE102004043009A1 (de) * 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
AU2006257411B2 (en) * 2005-06-17 2010-07-22 Merz Pharma Gmbh & Co. Kgaa Device and method for the production of biologically active compounds by fermentation
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica

Also Published As

Publication number Publication date
EP2170375A1 (en) 2010-04-07
WO2008145358A1 (en) 2008-12-04
TW200914039A (en) 2009-04-01
ZA200907875B (en) 2010-11-24
AU2008256419A1 (en) 2008-12-04
AR066782A1 (es) 2009-09-09
KR20100020971A (ko) 2010-02-23
MX2009012570A (es) 2010-03-15
TW200902050A (en) 2009-01-16
ZA200907874B (en) 2011-03-30
AU2008256418A1 (en) 2008-12-04
BRPI0812322A2 (pt) 2014-11-25
BRPI0812245A2 (pt) 2014-10-21
EP2164861A1 (en) 2010-03-24
RU2009149604A (ru) 2011-07-20
US20090028906A1 (en) 2009-01-29
CN101720331A (zh) 2010-06-02
CA2686642A1 (en) 2008-12-04
JP2010529000A (ja) 2010-08-26
MX2009012990A (es) 2010-04-01
US20090010965A1 (en) 2009-01-08
IL202130A0 (en) 2010-06-16
JP2010528999A (ja) 2010-08-26
CA2686637A1 (en) 2008-12-04
WO2008145359A1 (en) 2008-12-04
CN101687018A (zh) 2010-03-31
IL202129A0 (en) 2010-06-16
KR20100020972A (ko) 2010-02-23

Similar Documents

Publication Publication Date Title
AR066783A1 (es) Proceso para proporcionar un relajante muscular estable a la temperatura a base del componente neurotoxico de toxina botulinica
TR200706710U (tr) Elektroluminesans donatılmış eşya.
ECSP11011541A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
BRPI0615347A2 (pt) toleráncia ao estresse em plantas
CY1118508T1 (el) Συνθεση υδατανθρακων λαμβανομενη απο μεσογειακους καρπους
WO2006134190A3 (es) Agentes y métodos basados en el uso del dominio eda de la fibronectina
TW200606210A (en) Polythiophene formulations for improving organic light-emitting diodes
TW200710198A (en) Organic electroluminescent device
BRPI0716296A2 (pt) 'composição, artigo, estrutura laminada,dispersão,artigo moldado por injeção ,artigo moldado ,artigo para calçados e peça automotiva
MX2011004539A (es) Jabones espumables antimicrobianos.
GB2456466A (en) Sanitizing surfaces
BRPI0607782A2 (pt) misturas aditivas para artigos agrìcolas
BRPI0910964A2 (pt) método para tratamento da superficie de calçados, bolsas, luvas, outros artigos de couro ou artigos tipo couro, e, aparelho para impregnação de artigos
ECSP11011021A (es) Antagonistas de la via hedgehog de ftalazina disustituida
BR112014007306A2 (pt) artigos extrudados homogêneos feitos a partir de poliuretanos termoplasticamente processáveis com base em poliéster-dióis formados a partir de ácido succínico e de 1,3-propanodiol
DE602006009382D1 (de) Niedrigtemperaturdeckschicht
BRPI0514188A (pt) caramelos duros com perfil organoléptico melhorado, em particular, estáveis em armazenamento
WO2010039819A3 (en) Compositions for use in identification of fungi
BRPI0515476A (pt) maço com preservação do frescor para artigos oblongos
PL1941019T3 (pl) Kompozycja chemiczna i zastosowania
BR112015027735A8 (pt) componente automotivo compreendendo material compósito
Helal et al. Involvement of PVL Producing MRSA in Pneumonia, Cairo, Egypt
TH156825A (th) องค์ประกอบที่ประกอบรวมด้วย c5 และ c6 มอนอแซคคาไรด์
TH1801001624A (th) สิ่งของขึ้นรูปและวิธีการสำหรับทำการผลิตสิ่งของขึ้นรูป
TR200702259U (tr) Plastik yapıya sahip sandık.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal